Avidity Biosciences — Investor Day (June 2025)
38 slides from Avidity Biosciences's investor day presentation, Jun 9, 2025
Slide 1: Investor & Analyst Event Series: Delivering for People Living with FSHD
June 9, 2025 NASDAQ: RNA | aviditybio.com Investor & Analyst Event Series Delivering for People Living with Facioscapulohumeral Muscular Dystrophy (FSHD) Exhibit 99.1
Slide 2: Forward-Looking Statements
Forward-Looking Statements We caution the reader that this presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements other than statements of historical fact contained in this presentation are forward-looking statements. Forward-looking stateme
Slide 3: Our Vision
OUR VISION To profoundly improve people’s lives by revolutionizing the delivery of RNA therapeutics Amy Living with FSHD Josh Living with FSHD
Slide 4: Poised for three successive BLA submissions in 12 months
mAb OLIGO delpacibart braxlosiran abbreviation: del-brax Poised for three successive BLA submissions in 12 months starting year-end 2025 Share FDA confirmation of accelerated approval pathway in US 1 Present FORTITUDE™ 12 Month Topline Data 2 Announce initiation of global confirmatory Phase 3 study
Slide 5: Accelerating del-brax Toward Approval
Accelerating del-brax Toward Approval Accelerated Approval Pathway is Open Consistent and Reproducible Topline Data Global Confirmatory Phase 3 Study Initiated Written confirmation from FDA that accelerated approval pathway is open Primary endpoint is reduction in circulating biomarker, cDUX™ Antici
Slide 6: Avidity Management Team and Guest Speaker
Jeffrey M. Statland, M.D. Professor of Neurology, University of Kansas Medical Center Steve Hughes, M.D. Chief Medical Officer Sarah Boyce President & CEO Michael Flanagan, Ph.D. Chief Scientific Officer Kat Lange Chief Business Officer Delivering for People Living with FSHD AVIDITY MANAGEMENT TEAM
Slide 7: Agenda
Agenda Delivering for People Living with FSHD Sarah Boyce, President & CEO Advancing the First Potential FSHD Treatment Toward Regulatory Approvals Steve Hughes, M.D., CMO FORTITUDE™ Topline Data Jeffrey M. Statland, M.D., Professor of Neurology, University of Kansas Medical Center A Game-Changing C
Slide 8: FORTITUDE Topline Readout Study Design
FORTITUDE™ 12 Month Topline Readout Randomized, double-blind, placebo-controlled study FSHD participants ages 18-65 Primary and Secondary Objectives 2:1 Randomization Del-brax: Placebo (N = 12) (N = 27) Dose Booster Muscle biopsies to be performed at Baseline and 4 months Multidose quarterly with 1
Slide 9: Baseline Demographics and Characteristics
Baseline Demographics and Characteristics Placebo N=13 % or mean (SD) Del-brax 2 mg/kg* N=8 % or mean (SD) Del-brax 4 mg/kg N=18 % or mean (SD) Sex, % Male 92.3 62.5 50.0 Age, years 52.1 (9.92) 51.6 (11.62) 45.2 (11.49) Genetic Diagnosis, % FSHD 1 100 100 100 FSHD Clinical Score 9.2 (2.28) 9.3 (2.31
Slide 10: Del-brax: Favorable Long-Term Safety and Tolerability
Del-brax: Favorable Long-Term Safety and Tolerability Including OLE Subjects with ≥ 1 AE n (%) Placebo N=13 2 mg/kg* N=8 4 mg/kg N=18 OLE** N=38 Any AE 12 (92.3%) 8 (100%) 18 (100%) 21 (55.3) Related to study drug 3 (23.1%) 6 (75%) 11 (61.1%) 9 (23.7%) Severe AE 0 0 0 2 (5.3%) Serious AE (SAE) 0 0 0
Slide 11: Agenda
Agenda Delivering for People Living with FSHD Sarah Boyce, President & CEO Advancing the First Potential FSHD Treatment Toward Regulatory Approvals Steve Hughes, M.D., CMO FORTITUDE™ Topline Data Jeffrey M. Statland, M.D., Professor of Neurology, University of Kansas Medical Center A Game-Changing C
Slide 12: Jeffrey M. Statland, M.D. biography
Jeffrey M. Statland, M.D. is a Professor of Neurology at the University of Kansas Medical Center in Kansas City, Kansas. His research background has centered primarily on describing the natural history of and response to therapy for neuromuscular diseases. He completed a neuromuscular fellowship in
Slide 13: Facioscapulohumeral Muscular Dystrophy (FSHD)
Facioscapulohumeral Muscular Dystrophy (FSHD) Rare, hereditary disorder causing relentless loss of muscle function and progressive disability One of the most common forms of muscular dystrophy, FSHD causes progressive muscle weakness, pain, fatigue and disability Onset typically occurs in teenage or
Slide 14: What Matters to Patients is to Have Their Disease Under Control
What Matters to Patients is to Have Their Disease Under Control Over 60% of patients express that slowing or stopping the loss of muscle function would be the most meaningful outcome FSHD Voice of the Patient (June 2020) highlighted that the most meaningful outcome for patients is to slow or stop th
Slide 15: Improved Functional Mobility: 10MWRT
Improved Functional Mobility in del-brax Treated Participants Compared to Placebo Data at 12 months with Q13W dosing 10MWRT Change in seconds All del-brax data shown in this presentation is as of the May 2025 data cutoff date. All data shown are mean change (± SEM) from Baseline to Month 12. 2mg/kg
Slide 16: Improved Functional Mobility: TUG
Improved Functional Mobility in del-brax Treated Participants Compared to Placebo Data at 12 months with Q13W dosing TUG Change in seconds All data shown are mean change (± SEM) from Baseline to Month 12. 2mg/kg and 4mg/kg treatment arms pooled. TUG = timed up-and-go; maximal effort. One placebo par
Slide 17: Improved Strength in del-brax Treated Participants
Improved Strength in del-brax Treated Participants Compared to Placebo All data shown are mean change (± SEM) from Baseline to Month 12. QMT = quantitative muscle testing, PPN = percent predicted normal. One placebo participant had an unreliable baseline measurement and was removed from all analyses
Slide 18: Improved Upper Limb Function
Improved Upper Limb Function in del-brax Treated Participants Compared to Placebo Data at 12 months with Q13W dosing RWS Change in RSA All data shown are mean change (± SEM) from Baseline to Month 12. RWS = Reachable Workspace; RSA = Relative Surface Area. One placebo participant had an unreliable b
Slide 19: Improved Functional Mobility Relative to Placebo Exceeding MCID
Improved Functional Mobility in del-brax Treated Participants Relative to Placebo Exceeding MCID at Both Doses All data shown are mean difference (± SEM) between del-brax and placebo for change from baseline at Month 12. TUG, maximal effort One placebo participant had an unreliable baseline measurem
Slide 20: Improved Strength and Upper Limb Mobility Relative to Placebo
Improved Strength and Upper Limb Mobility in del-brax Treated Participants Relative to Placebo All data shown are mean difference (± SEM) between del-brax and placebo for change from baseline at Month 12. One placebo participant had an unreliable baseline measurement and was removed from all analyse
Slide 21: Improved Quality of Life: Fatigue, Sleep, Function
Fatigue Sleep Disturbance Improved Quality of Life in del-brax Treated Participants Compared to Placebo Data at 12 months with Q13W dosing Physical Function Upper Extremity All data shown are mean change (± SEM) from Baseline to Month 12. One placebo participant had an unreliable baseline measuremen
Slide 22: Improved Quality of Life: Pain and Overall Health
Improved Quality of Life in del-brax Treated Participants Compared to Placebo Data at 12 months with Q13W dosing All data shown are mean change (± SEM) from Baseline to Month 12. VAS = Visual Assessment Score. One placebo participant had an unreliable baseline measurement and was removed from all an
Slide 23: On Track to be First Disease-Modifying Treatment for People with FSHD
On Track to be First Disease-Modifying Treatment for People with FSHD 12-month analysis showed del-brax treated participants compared to placebo: Improved functional mobility measured by 10MWRT and TUG Improved muscle strength measured by QMT Improved quality of life as measured by patient reported
Slide 24: Agenda
Agenda Delivering for People Living with FSHD Sarah Boyce, President & CEO Advancing the First Potential FSHD Treatment Toward Regulatory Approvals Steve Hughes, M.D., CMO FORTITUDE™ Topline Data Jeffrey M. Statland, M.D., Professor of Neurology, University of Kansas Medical Center A Game-Changing C
Slide 25: cDUX: A Game-Changing Circulating Biomarker
Rapid and statistically significant reduction in cDUX in del-brax treated participants Rapid and consistent reductions in CK, an indicator of muscle damage Participants crossing over to del-brax showed rapid drop in CK cDUX is elevated 6- to 9-fold in people living with FSHD compared to healthy volu
Slide 26: cDUX is KHDC1L: DUX4-Regulated Circulating Biomarker
cDUX™ is KHDC1L: A Game-Changing DUX4-Regulated Circulating Biomarker Multi-year Discovery Process FSHD & Healthy Biopsies Plasma from FSHD & Healthy Volunteers Tapscott Lab & Disease Expertise K-homology domain-containing 1 like (KHDC1L) is an RNA-binding protein implicated in germ-cell biology and
Slide 27: Rapid, Significant Decrease in cDUX and Creatine Kinase
Rapid, Significant and Consistent Decrease in cDUX™ and Creatine Kinase Circulating Biomarkers Following del-brax Treatment For both cDUX and CK, data represents mean percent change from baseline (averaged screen + day 1 pre-dose) ± SEM. Placebo (n = 13) and pooled del-brax 2mg/kg and 4mg/kg treatme
Slide 28: Placebo Participants Transitioning to del-brax Showed Reductions in Creatine Kinase
Placebo Participants Transitioning to del-brax Showed Rapid and Consistent Reductions in Creatine Kinase Mean percent change from baseline (averaged screen + day 1 pre-dose) ± SEM; FORTITUDE: pooled del-brax 2mg/kg and 4mg/kg treatment arms (n = 26) or placebo (PBO; n = 13); FORTITUDE-OLE del-brax t
Slide 29: Data Supports cDUX as Potential Accelerated Approval Endpoint
Compelling Data in FSHD Supports cDUX™ as a Potential Accelerated Approval Endpoint cDUX, a direct target of DUX4, is significantly elevated in people living with FHSD Sustained elevated cDUX levels are associated with disease severity and disease progression in ReSolve natural history study Direct
Slide 30: Agenda
Agenda Delivering for People Living with FSHD Sarah Boyce, President & CEO Advancing the First Potential FSHD Treatment Toward Regulatory Approvals Steve Hughes, M.D., CMO FORTITUDE™ Topline Data Jeffrey M. Statland, M.D., Professor of Neurology, University of Kansas Medical Center A Game-Changing C
Slide 31: FORTITUDE Biomarker Cohort Targeting Accelerated Approval
FORTITUDE™ Biomarker Cohort Targeting Accelerated Approval Placebo | Every 6 weeks Duration of Placebo Controlled Study: 12 months FORTITUDE Open Label Extension Trial 2:1 Randomization (N=51) TOPLINE ANALYSIS: 12 month Topline readout expected in Q2 2026 BLA submission anticipated in H2 2026 Phase
Slide 32: FORTITUDE Biomarker Cohort and FDA Written Confirmation
Biomarker cohort fully enrolled 12-month registrational study 2 mg/kg every 6 weeks Placebo-controlled, double blind, 2:1 randomization N=51*; ages 16‒70 Participants eligible to roll over into an open label extension FORTITUDE™ Biomarker Cohort FDA Written Confirmation that Accelerated Approval Pa
Slide 33: FORWARD Global Confirmatory Phase 3 Study Underway
FORWARD™ Global Confirmatory Phase 3 Study Underway Duration of Placebo Controlled Study: 18 Months Del-brax 2 mg/kg* | Every 6 weeks Placebo | Every 6 weeks Open Label Extension Trial 1:1 Randomization (N = 200) 78 Week Study Phase 3 FORWARD™ Study Ongoing FDA in alignment with FORWARD™ study desig
Slide 34: FORWARD Confirmatory Phase 3 Trial: Design and Objectives
2 mg/kg every 6 weeks N=200; Ages 16‒70 1:1 randomization Primary analysis at 18 months Participants eligible to roll-over into an open label extension ~45 global sites Confirmatory Study Design Key Registrational Endpoints* Additional Endpoints FORWARD™ Confirmatory Phase 3 Trial: Design and Objec
Slide 35: Agenda
Agenda Delivering for People Living with FSHD Sarah Boyce, President & CEO Advancing the First Potential FSHD Treatment Toward Regulatory Approvals Steve Hughes, M.D., CMO FORTITUDE™ Topline Data Jeffrey M. Statland, M.D., Professor of Neurology, University of Kansas Medical Center A Game-Changing C
Slide 36: Accelerating del-brax Toward Approval
Accelerating del-brax Toward Approval Accelerated Approval Pathway is Open Consistent and Reproducible Topline Data Global Confirmatory Phase 3 Study Initiated Written confirmation from FDA that accelerated approval pathway is open Primary endpoint is reduction in circulating biomarker, cDUX™ Antici
Slide 37: Our Vision
OUR VISION To profoundly improve people’s lives by revolutionizing the delivery of RNA therapeutics Amy Living with FSHD Amy Living with FSHD
Slide 38: Investor & Analyst Event Series: Delivering for People Living with FSHD
June 9, 2025 NASDAQ: RNA | aviditybio.com Investor & Analyst Event Series Delivering for People Living with Facioscapulohumeral Muscular Dystrophy (FSHD)